SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
28 11월 2023 - 10:25PM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, today announced successful results from a
pre-clinical trial performed by Professor Joseph Tam from The
Hebrew University of Jerusalem.
The trial was conducted as part of the collaboration between
SciSparc and Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CMND),
(FSE: CWY), a biotech company focused on the discovery and
development of novel psychedelic-derived therapeutics to solve
major under-treated health problems. The combination treatment
includes palmitoylethanolamide (PEA), an anti-inflammatory agent
and the active ingredient of the Company’s proprietary CannAmide™,
and MEAI, Clearmind’s novel proprietary psychedelic treatment for
various addictions, obesity, and depression (the “Combination
Treatment”).
The goal of the trial was to identify the optimal dosage for the
Combination Treatment and, in turn, observe the safety and impact
thereof on various metabolic and behavioral parameters including
fat oxidation, locomotor activity, and feeding behavior.
Fourteen different treatment groups were created (for a total of
84 animals) receiving single treatment doses ranging from 40, 20,
10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose
of 25 mg/kg. MEAI administration exhibited a meaningful degree of
tolerance, leaving the animals' viability unaffected across all
experimental groups. Similar results were also observed in groups
treated by the Combination Treatment, with the most prominent
effects observed when combining MEAI and PEA, particularly at 20
and 10 mg/kg.
Results indicated:
- The administered treatment exhibited a meaningful degree of
tolerance, leaving the mice's viability unaffected across all
experimental groups.
- Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to
increased oxygen consumption and carbon dioxide emission, coupled
with elevated energy expenditure and fat oxidation. The changed
rates of oxygen consumption and carbon dioxide emission indicate
increases in the metabolic process and fat burn.
- A notable reduction in food consumption (appetite) and meal
sizes was also observed, primarily at 40 and 20 mg/kg of MEAI.
- Slight elevations in carbohydrate oxidation were noted
particularly at 20 and 10 mg/kg.
- At 40 and 20 mg/kg significant reductions in ambulation was
noted, without affecting voluntary activity.
"I am encouraged by the positive results from our recent
pre-clinical trial, which represents another milestone in our
ongoing efforts to develop safe and effective innovative therapies.
The successful collaboration between SciSparc and Clearmind
continues to demonstrate the potential of our Combination Treatment
to address obesity and related health challenges," said Oz Adler,
SciSparc's Chief Executive Officer. "The trial's findings,
including increased metabolic activity, reduced appetite, and
enhanced fat oxidation, are promising indicators of the treatment's
efficacy and safety."
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI-210 for the treatment of
ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds’ oil-based products on
the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses: the potential of the Combination
Treatment in addressing obesity and related health challenges and
that the findings of the trial are promising indicators of the
treatment’s efficacy and safety. Because such statements deal with
future events and are based on SciSparc's current expectations,
they are subject to various risks and uncertainties and actual
results, performance or achievements of SciSparc could differ
materially from those described in or implied by the statements in
this press release. Historical results of scientific research and
clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions The forward-looking statements contained
or implied in this press release are subject to other risks and
uncertainties, including those discussed under the heading "Risk
Factors" in SciSparc's Annual Report on Form 20-F filed with the
SEC on May 1, 2023, and in subsequent filings with the U.S.
Securities and Exchange Commission. Except as otherwise required by
law, SciSparc disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date they were made, whether as a result of new information, future
events or circumstances or otherwise.
Investor Contact: IR@scisparc.com Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
SciSparc (NASDAQ:SPRC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024